Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin

References

• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five european countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121–132.
   PubMed Web of Science ®Google Scholar
• Sato Y, Yanagita M. Renal anemia: from incurable to curable. Am J Physiol Renal Physiol. 2013;305(9):F1239–F1248.
   PubMed Web of Science ®Google Scholar
• Tsagalis G. Renal anemia: a nephrologist's view. Hippokratia. 2011;15(1):39–43.
   PubMedGoogle Scholar
• Vos FE, Schollum JB, Coulter CV, et al. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011;58(4):591–598.
   PubMed Web of Science ®Google Scholar
• Li JH, Luo JF, Jiang Y, et al. Red blood cell lifespan shortening in patients with Early-Stage chronic kidney disease. Kidney Blood Press Res. 2019;44(5):1158–1165.
   PubMed Web of Science ®Google Scholar
• Ma J, Dou Y, Zhang H, et al. Correlation between inflammatory biomarkers and red blood cell life span in chronic hemodialysis patients. Blood Purif. 2017;43(1–3):200–205.
   PubMed Web of Science ®Google Scholar
• Sato Y, Mizuguchi T, Shigenaga S, et al. Shortened red blood cell lifespan is related to the dose of erythropoiesis-stimulating agents requirement in patients on hemodialysis. Ther Apher Dial. 2012;16(6):522–528.
   PubMed Web of Science ®Google Scholar
• Qadri SM, Bissinger R, Solh Z, et al. Eryptosis in health and disease: a paradigm shift towards understanding the (patho)physiological implications of programmed cell death of erythrocytes. Blood Rev. 2017;31(6):349–361.
   PubMed Web of Science ®Google Scholar
• Abed M, Artunc F, Alzoubi K, et al. Suicidal erythrocyte death in end-stage renal disease. J Mol Med (Berl). 2014;92(8):871–879.
   PubMed Web of Science ®Google Scholar
• Lang E, Qadri SM, Lang F. Killing me softly - suicidal erythrocyte death. Int J Biochem Cell Biol. 2012;44(8):1236–1243.
   PubMed Web of Science ®Google Scholar
• Ahmed MS, Langer H, Abed M, et al. The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res. 2013;37(2–3):158–167.
   PubMed Web of Science ®Google Scholar
• Ahmed MS, Abed M, Voelkl J, et al. Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate. BMC Nephrol. 2013;14:244.
   PubMed Web of Science ®Google Scholar
• Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004;44(4):715–719.
   PubMed Web of Science ®Google Scholar
• Cimen MY. Free radical metabolism in human erythrocytes. Clin Chim Acta. 2008;390(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Lang F, Abed M, Lang E, et al. Oxidative stress and suicidal erythrocyte death. Antioxid Redox Signal. 2014;21(1):138–153.
   PubMed Web of Science ®Google Scholar
• Garcia SC, Schott K, Charao M, et al. Quantification of reduced glutathione by HPLC-UV in erythrocytes of hemodialysis patients. Biomed Chromatogr. 2008;22(5):460–468.
   PubMed Web of Science ®Google Scholar
• Kempe DS, Lang PA, Duranton C, et al. Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J. 2006;20(2):368–370.
   PubMed Web of Science ®Google Scholar
• Myssina S, Huber SM, Birka C, et al. Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol. 2003;14(11):2750–2757.
   PubMed Web of Science ®Google Scholar
• Polenakovic M, Sikole A. Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol. 1996;7(8):1178–1182.
   PubMed Web of Science ®Google Scholar
• Schwartz AB, Kelch B, Terzian L, et al. One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. ASAIO Trans. 1990;36(3):M691–M696.
   PubMedGoogle Scholar
• Schwartz AB, Kahn SB, Kelch B, et al. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy. Clin Nephrol. 1992;38(5):283–289.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Roxadustat: first global approval. Drugs. 2019;79(5):563–572.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912–924.
   PubMed Web of Science ®Google Scholar
• Chang WT, Lo YC, Gao ZH, et al. Evidence for the capability of roxadustat (FG-4592), an oral HIF Prolyl-Hydroxylase inhibitor, to perturb membrane ionic currents: an unidentified yet important action. Int J Mol Sci. 2019;20(23):6027.
   Web of Science ®Google Scholar
• Long G, Chen H, Wu M, et al. Antianemia drug roxadustat (FG-4592) protects against Doxorubicin-Induced cardiotoxicity by targeting antiapoptotic and antioxidative pathways. Front Pharmacol. 2020;11:1191.
   PubMed Web of Science ®Google Scholar
• Strocchi A, Schwartz S, Ellefson M, et al. A simple carbon monoxide breath test to estimate erythrocyte turnover. J Lab Clin Med. 1992;120(3):392–399.
   PubMed Web of Science ®Google Scholar
• Zhang HD, Ma YJ, Liu QF, et al. Human erythrocyte lifespan measured by levitt’s CO breath test with newly developed automatic instrument. J Breath Res. 2018;12(3):36003.
   Web of Science ®Google Scholar
• Ye L, Ji Y, Zhou C, et al. Comparison of levitt’s CO breath test and the 15 N-glycine labeling technique for measuring the lifespan of human red blood cells. Am J Hematol. 2021;96(10):1232–1240.
   PubMed Web of Science ®Google Scholar
• Birka C, Lang PA, Kempe DS, et al. Enhanced susceptibility to erythrocyte “apoptosis” following phosphate depletion. Pflugers Arch. 2004;448(5):471–477.
   PubMed Web of Science ®Google Scholar